| Issue Date | Title | Author(s) |
| 1-Feb-2016 | Allogeneic transplantation for CML in the TKI era: striking the right balance | Innes, AJ; Milojkovic, D; Apperley, JF; , et al |
| 1-Jul-2017 | BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency | Afzali, B; Gronholm, J; Vandrovcova, J; O'Brien, C; Sun, H-W, et al |
| 1-May-2016 | Chronic myeloid leukemia: reminiscences and dreams. | Mughal, TI; Radich, JP; Deininger, MW; Apperley, JF; Hughes, TP, et al |
| 28-Jul-2016 | Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia | Claudiani, S; Apperley, JF; Deplano, S; Khorashad, J; Foroni, L, et al |
| 4-Mar-2016 | Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States | Padula, WV; Larson, RA; Dusetzina, SB; Apperley, JF; Hehlmann, R, et al |
| 26-May-2017 | De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial | Clark, RE; Polydoros, F; Apperley, JF; Milojkovic, D; Pocock, C, et al |
| 1-Jun-2016 | DE-ESCALATION OF TYROSINE KINASE INHIBITOR THERAPY IS SAFE IN CHRONIC MYELOID LEUKAEMIA IN DURABLE MOLECULAR RESPONSE (>= MR3 FOR >= 12 MONTHS): INITIAL RESULTS IN THE BRITISH DESTINY STUDY | Clark, R; Polydoros, F; Apperley, J; Pocock, C; Smith, G, et al |
| 9-Oct-2021 | Genomic abnormalities as biomarkers and therapeutic targets in acute myeloid leukaemia | Ribeiro, S; Eiring, A; Sorouri Khorashad, J; |
| Feb-2013 | Interaction between haematopoietic and mesenchymal stroma | Dazzi, Francesco; Trento, Cristina; |
| 14-Feb-2017 | Lineage-specific genes are prominent DNA damage hotspots during leukemic transformation of B-cell precursors | Boulianne, B; Robinson, ME; May, PC; Castellano, L; Blighe, K, et al |
| 3-Mar-2017 | Monomeric, porous type II collagen scaffolds promote chondrogenic differentiation of human bone marrow mesenchymal stem cells in vitro | Tamaddon, M; Burrows, M; Ferreira, SA; Dazzi, F; Apperley, JF, et al |
| Apr-2016 | Personalised genetic management of CML | Reid, Alistair; Apperley, Jane; Foroni, Letizia; Alikian, Mary; , et al |
| 1-Jun-2016 | PRESENCE OF SOMATIC AND GERMLINE MUTATIONS IN EPIGENETIC MODIFIERS IN CML-CP | Nteliopoulos, G; Bazeos, A; Gerrard, G; Alikian, M; Foong, HE, et al |
| Sep-2015 | Role of natural killer cells in cord blood transplantation | Armstrong-James, Darius; Rezvani, Katayoun; Sekine, Takuya; |
| 15-Jun-2019 | SSB1/SSB2 proteins safeguard B-cell development by protecting the genomes of B-cell precursors | Pfeifer, M; Brem, R; Lippert, T; Boulianne, B; Ho, HN, et al |
| 30-Nov-2018 | The argument for using imatinib in CML | Claudiani, S; Apperley, JF; , et al |